LaNova Medicines
LaNova Medicines (礼新医药) is a Shanghai-based clinical-stage biotech founded in 2019 developing antibody-based oncology therapeutics (ADCs, bispecifics, monoclonal antibodies) targeting the tumor microenvironment, with eight clinical-stage programs and a business model centered on out-licensing pipeline assets to global pharmaceutical partners.
- Company typePrivate
- Founded2019
- HeadquartersShanghai, China
- Headcount101–250
- GTM typeB2B
- OfferingServices
What LaNova Medicines does
LaNova Medicines (礼新医药) is a clinical-stage biotechnology company founded in 2019 and headquartered in Shanghai's Zhangjiang Science Park. The company focuses on immuno-oncology and tumor microenvironment drug development, with particular emphasis on targeting difficult multi-transmembrane proteins (notably GPCRs) that are challenging for conventional antibody discovery approaches. Its pipeline addresses solid tumors (gastric, pancreatic, lung, colorectal, head and neck cancers) and hematological malignancies (multiple myeloma), serving patients with resistance to existing PD-1 checkpoint inhibitors and tumors with low antigen expression where current therapies underperform.
The company operates three proprietary technology platforms: LM-Abs™ (a multi-transmembrane protein antibody discovery platform covering discovery, screening, optimization, and humanization); LM-ADC™ (a next-generation ADC platform with proprietary linker-payload combinations including MMAE, eribulin, and LDX2 topoisomerase-based variants); and LM-TCE™/SynICE™ (an immune cell engager bispecific antibody platform enabling tumor-antigen-dependent conditional immune cell activation). As of June 2025, LaNova had 8 clinical-stage programs including LM-302 (Claudin 18.2 ADC, Phase III), LM-108 (CCR8 mAb, Phase II), LM-305 (GPRC5D ADC, licensed to AstraZeneca), LM-299 (PD-1/VEGF bispecific, licensed to Merck/MSD), LM-101 (SIRPα mAb), LM-24C5 (CEACAM5/4-1BB bispecific), LM-168 (next-gen CTLA-4), and LM-317 (NaPi2b bispecific ADC), plus a preclinical pipeline of additional ADC and bispecific candidates. The platform portfolio is supported by over 30 global invention patents.
LaNova's business model centers on out-licensing proprietary pipeline assets to global pharmaceutical partners for clinical development and commercialization in exchange for upfront payments, development and commercial milestones, and tiered royalties. Disclosed licensing deal value exceeds $3.8 billion across partnerships with Merck (LM-299: $588M upfront plus up to $2.7B in milestones), AstraZeneca (LM-305: $55M upfront plus up to $545M), and Turning Point Therapeutics/BMS (LM-302: $25M upfront plus up to $1B+). The company has raised approximately $420M across venture financing rounds (Series A 2020 through Series C1 in October 2024) from investors including Qiming Venture Partners and Sino Biopharmaceutical. In July 2025, LaNova was acquired by Sino Biopharmaceutical for approximately $951 million, with the company now operating as a subsidiary within Sino Biopharm's diversified pharmaceutical portfolio.
LaNova Medicines firmographics
Firmographics- Name
- LaNova Medicines
- Legal name
- 礼新医药科技（上海）有限公司
- Website
- https://lanovamedicines.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- LaNova Medicines (礼新医药) is a Shanghai-based clinical-stage biotech founded in 2019 developing antibody-based oncology therapeutics (ADCs, bispecifics, monoclonal antibodies) targeting the tumor microenvironment, with eight clinical-stage programs and a business model centered on out-licensing pipeline assets to global pharmaceutical partners.
- Ownership category
- akta.pro rank
LaNova Medicines industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
Keywords
Where LaNova Medicines is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices2 records
Markets served
LaNova Medicines business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- Out-licensing/Strategic Partnerships: LaNova generates revenue through out-licensing its proprietary pipeline assets to global pharmaceutical companies. This includes upfront payments, development and commercial milestone payments, and tiered royalties on net sales. Major deals include LM-302 to Turning Point ($25M upfront + up to $1B+), LM-305 to AstraZeneca ($55M upfront + $545M milestones), and LM-299 to Merck ($588M upfront + $2.7B milestones).
- Equity Financing: Company raises capital through venture financing rounds. Completed Series A (2020), Series B (2023), and Series C1 (October 2024, raising RMB 300 million / ~$42 million). Investors include Qiming Venture Partners, Sino Biopharmaceutical, and other institutional investors.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
LaNova Medicines product offering
Product offeringCore offering
LaNova Medicines is a clinical-stage biotech company that develops antibody-based oncology therapeutics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies. The company operates three proprietary technology platforms (LM-Abs™, LM-ADC™, LM-TCE™) and out-licenses its clinical-stage pipeline assets to global pharmaceutical partners for development and commercialization, generating revenue through upfront payments, development and commercial milestones, and tiered royalties.
Product overview
LaNova Medicines is a clinical-stage biotech company with three proprietary technology platforms: LM-Abs™ for multi-transmembrane protein antibody discovery (particularly GPCRs), LM-ADC™ for next-generation ADC development with proprietary linker-payload technologies, and LM-TCE™ (SynICE™) for bispecific antibody immune cell engagers. The company operates a diversified pipeline of 8 clinical-stage programs and multiple preclinical programs. Key products include: LM-302 (Claudin 18.2 ADC, Phase III, licensed to BMS/Turning Point), LM-108 (CCR8 mAb, Phase II), LM-299 (PD-1/VEGF bispecific, Phase I, licensed to Merck/MSD), LM-305 (GPRC5D ADC, Phase I, licensed to AstraZeneca), LM-101 (SIRPα mAb), LM-24C5 (CEACAM5/4-1BB bispecific), LM-168 (next-gen CTLA-4), and LM-317 (NaPi2b ADC). Preclinical pipeline includes ADCs targeting CDH17 (LM-350), undisclosed targets (LM-364, LM-338), and bispecific antibodies (LM-2199, LM-339).
Differentiator
Problem solved
Functional benefit
Products and services
- LM-302 (Anti-Claudin 18.2 ADC) Claudin 18.2-targeting antibody-drug conjugate consisting of a Claudin 18.2-specific antibody linked to MMAE toxin via VC-PAB cleavable linker. Indicated for gastric/GEJ adenocarcinoma and pancreatic cancer. Licensed globally (excluding Greater China and Korea) to Turning Point Therapeutics (BMS).
- LM-108 (Anti-CCR8 mAb) CCR8-targeting monoclonal antibody that selectively depletes tumor-infiltrating Tregs via ADCC without affecting peripheral Tregs. In Phase II clinical development for MSI-H solid tumors and gastric cancer, with potential for PD-1 resistant patients.
- LM-305 (Anti-GPRC5D ADC) GPRC5D-targeting antibody-drug conjugate with MMAE payload for multiple myeloma treatment. First-in-class potential as the first anti-GPRC5D ADC to enter clinical stage worldwide.
- LM-299 (Anti-PD-1/VEGF Bispecific Antibody) PD-1/VEGF bispecific antibody simultaneously blocking PD-1/PD-L1 and VEGF/VEGFR signaling pathways for synergistic tumor immunity and anti-angiogenesis. Licensed globally to Merck (MSD).
- LM-101 (Anti-SIRPα mAb) SIRPα-targeting monoclonal antibody for solid tumors and hematologic malignancies. Phase I clinical stage, with potential to synergize with anti-PD-1 and ADC therapies.
- LM-24C5 (Anti-CEACAM5/4-1BB Bispecific Antibody) CEACAM5 and 4-1BB bispecific antibody for CRC, GI cancer, and lung cancer. Phase I/II clinical stage with conditional T-cell activation mechanism to enhance anti-tumor immunity.
- LM-168 (Next-Generation Anti-CTLA4 mAb) Next-generation tumor-specific anti-CTLA4 monoclonal antibody designed with improved efficacy and reduced toxicity profile compared to conventional CTLA-4 inhibitors.
- LM-2417 (Anti-NaPi2b Bispecific Antibody) NaPi2b-targeting bispecific antibody for lung cancer and ovarian cancer. ADC format, received FDA IND approval.
- LM-350 (Anti-CDH17 ADC) CDH17-targeting antibody-drug conjugate for colorectal cancer, pancreatic cancer, and gastric cancer. Received NMPA IND approval and FDA IND clearance.
Quantifiable outcome
- LM-302 demonstrated favorable safety and efficacy in Claudin 18.2 positive tumors including those with low expression levels
- +2 more outcomes
Companies that use LaNova Medicines
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles1 record
LaNova Medicines technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
LaNova Medicines partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Merck (MSD)coreMerck acquired global exclusive license for LM-299 (PD-1/VEGF bispecific antibody, also known as MK-2010) for $588 million upfront plus up to $2.7 billion in potential milestones. LaNova retains certain co-development rights. The compound showed Phase 1/2 data at AACR 2026 with competitive ORR rates in NSCLC.
- CTTQ/正大天晴minorClinical collaboration for combination therapy using LaNova's LM-108 (CCR8 antibody) with CTTQ's benmelstobart (PD-L1 inhibitor) and penpulimab (PD-1 inhibitor) in solid tumors. NMPA approved the combination IND in October 2024.
- AstraZenecacoreAstraZeneca acquired global exclusive license for LM-305 (GPRC5D-targeting ADC for multiple myeloma) with $55 million upfront payment and up to $545 million in development and commercial milestones, plus tiered royalties on net sales. LM-305 is the first GPRC5D-targeting ADC to enter clinical stage globally.
- Turning Point Therapeutics (Bristol Myers Squibb)coreTurning Point (now part of BMS) acquired exclusive license for LM-302 (Claudin 18.2 ADC) in all territories except Greater China and South Korea for $25 million upfront, up to $1 billion in milestones, and tiered royalties. Deal also includes option to collaborate on up to three additional ADC programs.
- CBMG (西比曼生物)minorStrategic partnership for solid tumor treatment combining LaNova's antibody-based therapeutics with CBMG's cell therapy products including CAR-T and TIL candidates.
- Junshi BiosciencesminorCollaboration on combination therapy clinical trials combining LaNova's LM-302 (Claudin 18.2 ADC) with Junshi's PD-1 inhibitor toripalimab for treatment of advanced gastrointestinal tumors.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
LaNova Medicines competitors and assessment
Company assessmentDirect peers
- Akeso (康方生物): Chinese clinical-stage biotech developing bispecific antibodies and immuno-oncology therapies (e.g., ivonescimab PD-1/VEGF bispecific). Directly comparable to LaNova in bispecific antibody focus, oncology pipeline, and Chinese biotech context with global ambitions.
- RemeGen: Chinese clinical-stage biotech with strong ADC and bispecific antibody pipeline (e.g., disitamab vedotin). Closely comparable to LaNova in therapeutic modalities, oncology focus, and target selection including Claudin 18.2.
- Innovent Biologics: Leading Chinese biologics developer with oncology antibody pipeline including PD-1 (sintilimab) and multiple bispecific/ADC programs. Comparable in clinical-stage antibody development and global out-licensing activities.
- Alphamab Oncology (康宁杰瑞): Chinese clinical-stage biotech specializing in bispecific antibodies and oncology biologics (e.g., KN046 PD-L1/CTLA-4 bispecific). Highly comparable to LaNova in bispecific antibody modality and oncology focus.
- Duality Biologics: Chinese clinical-stage ADC developer with proprietary linker-payload technology and multiple oncology ADC programs. Directly comparable to LaNova in ADC platform technology and out-licensing model.
- Cstone Pharmaceuticals: Chinese clinical-stage oncology biotech with multiple antibody programs and global pharma partnerships (including with Pfizer). Comparable in clinical-stage profile, oncology focus, and partnership-driven business model.
Broad incumbents
- Hansoh Pharmaceutical: Large established Chinese pharmaceutical company with significant biologics portfolio including oncology antibodies and ADCs. Broader and more diversified than LaNova but overlapping in oncology antibody development.
- Junshi Biosciences: Chinese biotech that developed China's first approved PD-1 (toripalimab), with a LaNova collaboration on LM-302 combinations. Comparable in immuno-oncology antibody focus and global development ambitions.
- BeiGene: Large globally commercialized Chinese biotech with oncology biologics portfolio including Brukinsa. Significantly larger than LaNova but overlapping in oncology antibody development and clinical execution.
Emerging players
- Mersana Therapeutics: US clinical-stage ADC developer with proprietary linker-payload technology platforms (Dolasynthen, Immunosynthen). Comparable to LaNova in ADC platform focus and clinical-stage development, though US-based.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
LaNova Medicines social profiles
Digital presenceLaNova Medicines compliance and trust
Trust signalCompliance3 records
LaNova Medicines financial estimates
Financial estimateRevenue estimate
Valuation estimate
LaNova Medicines leadership team
Management profileNumber of profiles
Profiles1 record
LaNova Medicines funding detail
Funding detailFunding overview
Funding rounds7 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LaNova Medicines M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LaNova Medicines
What does LaNova Medicines do?
LaNova Medicines is a clinical-stage biotech company that develops antibody-based oncology therapeutics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies. The company operates three proprietary technology platforms (LM-Abs™, LM-ADC™, LM-TCE™) and out-licenses its clinical-stage pipeline assets to global pharmaceutical partners for development and commercialization, generating revenue through upfront payments, development and commercial milestones, and tiered royalties.
Is LaNova Medicines a public or private company?
LaNova Medicines is a private company. It is classified as corporate owned and is currently acquired.
When was LaNova Medicines founded?
LaNova Medicines was founded in 2019. It employs 101 to 250 people.
Where is LaNova Medicines based?
LaNova Medicines is headquartered in Shanghai, China, in the Asia region.
How does LaNova Medicines make money?
Two revenue lines are on record. Out-licensing/Strategic Partnerships are the primary driver. The others are equity Financing.
Who are LaNova Medicines's main competitors?
Direct peers on record are Akeso (康方生物), RemeGen, Innovent Biologics, Alphamab Oncology (康宁杰瑞), Duality Biologics and Cstone Pharmaceuticals. Broad incumbents are Hansoh Pharmaceutical, Junshi Biosciences and BeiGene. Mersana Therapeutics is listed as an emerging player.
Does LaNova Medicines have an API?
No public API is recorded for LaNova Medicines.
What industry is LaNova Medicines in?
LaNova Medicines's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.